Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Corsodyl Original Dentifrice is a specialized toothpaste developed by Haleon (formerly GSK Consumer Healthcare) for the treatment and prevention of gingivitis and the reduction of dental plaque. Its formulation is characterized by a high concentration (67%) of sodium bicarbonate (NaHCO3) combined with sodium fluoride (NaF) at approximately 1400 ppm. The primary mechanism of action involves sodium bicarbonate penetrating the dental plaque biofilm matrix and disrupting the chemical bonds that hold the biofilm together. This process loosens and softens the plaque, making it significantly easier to remove through mechanical brushing. Clinical studies, including randomized controlled trials, have shown that twice-daily use of this 67% sodium bicarbonate dentifrice significantly reduces gingival bleeding, plaque index scores, and gingival inflammation compared to standard fluoride toothpastes. It is marketed under various names, including Parodontax and Corsodyl Daily Gum and Toothpaste, depending on the region.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on sodium bicarbonate + sodium fluoride.